The Second Affiliated Hospital of Soochow University

The Second Affiliated Hospital of Soochow University (Nuclear Industry General Hospital, Sino-France Friendship Hospital, Suzhou Sixth People's Hospital) was founded in December 1988 and is a tertiary Grade A hospital integrating medical care, teaching, research, prevention and emergency response. It serves as the Fourth Clinical Department of the National Health Commission's Nuclear Accident Medical Emergency Center. On October 31, 1992, it became the first hospital in China to be designated as a Sino-France Friendship Hospital. It has established close exchange and cooperation relationships with French institutions including the Paris Public Health Administration and universities in Montpellier, Strasbourg, Nantes, and Grenoble, sending over 60 medical staff to France for advanced study and bringing back laparoscopic technology to fill a gap in Suzhou. With over 2,600 approved beds across four campuses — Sanxiang Road, Xuguan, Luoxiang Road, and Xihuan Road — the hospital operates 53 clinical and medical technology departments, employs over 3,700 staff, including more than 760 senior experts. Its neurosurgery keyhole technology leads the nation, general surgery serves as a Ministry of Health endoscopic technology training base, radiation therapy is a pioneer in precise cancer treatment in Jiangsu, and vascular surgery, plastic surgery, and hand surgery fill gaps in Suzhou. Adhering to the motto of "benevolence, sincerity, innovation, transcendence," the hospital is a National Clinical Medicine Postdoctoral Mobile Station, Clinical Medicine Doctoral/Master's Degree Granting Unit, Resident Physician Standardized Training Base, and National Drug Clinical Trial Base. Ranked third in the 2022 national performance assessment of tertiary public hospitals (non-annual report group), it has been honored as a National Research Hospital Construction Unit and Jiangsu High-Quality Development Pilot Hospital. In February 2025, it completed the world's first yttrium-90 carbon microsphere injection clinical research for pancreatic cancer. The hospital supports international commercial insurance direct billing, partnering with MSH CHINA, MediLink-Global, and other international insurers.